- Home
- ABSI vs PRTA Comparison
ABSI vs PRTA Comparison
Compare ABSI & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- PRTA
- Stock Information
- Founded
- ABSI 2011
- PRTA 2012
- Country
- ABSI United States
- PRTA Ireland
- Employees
- ABSI N/A
- PRTA N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- PRTA Health Care
- Exchange
- ABSI Nasdaq
- PRTA Nasdaq
- Market Cap
- ABSI 338.0M
- PRTA 472.1M
- IPO Year
- ABSI 2021
- PRTA N/A
- Fundamental
- Price
- ABSI $2.39
- PRTA $8.20
- Analyst Decision
- ABSI Strong Buy
- PRTA Buy
- Analyst Count
- ABSI 5
- PRTA 10
- Target Price
- ABSI $7.98
- PRTA $14.86
- AVG Volume (30 Days)
- ABSI 4.4M
- PRTA 1.2M
- Earning Date
- ABSI 08-12-2025
- PRTA 08-04-2025
- Dividend Yield
- ABSI N/A
- PRTA N/A
- EPS Growth
- ABSI N/A
- PRTA N/A
- EPS
- ABSI N/A
- PRTA N/A
- Revenue
- ABSI $4,138,000.00
- PRTA $10,341,000.00
- Revenue This Year
- ABSI $44.71
- PRTA N/A
- Revenue Next Year
- ABSI $374.26
- PRTA $389.77
- P/E Ratio
- ABSI N/A
- PRTA N/A
- Revenue Growth
- ABSI 27.32
- PRTA N/A
- 52 Week Low
- ABSI $2.01
- PRTA $4.32
- 52 Week High
- ABSI $6.33
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- ABSI 33.33
- PRTA 58.73
- Support Level
- ABSI $2.50
- PRTA $8.05
- Resistance Level
- ABSI $2.73
- PRTA $8.73
- Average True Range (ATR)
- ABSI 0.18
- PRTA 0.38
- MACD
- ABSI -0.04
- PRTA -0.05
- Stochastic Oscillator
- ABSI 1.94
- PRTA 47.62
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.